[PRESS RELEASE] – STAMFORD, Conn., Nov. 10, 2026 – Curaleaf Holdings Inc., a leading international provider of consumer and medical cannabis products, announced that it has received competition law clearances in Germany and Canada for its proposed acquisition of Aurora Cannabis Inc. Germany and Canada are the only jurisdictions in which competition law clearance was required for Curaleaf's proposed acquisition.
On Oct. 20, 2026, Germany's Federal Ministry for Economic Affairs and Energy granted approval for the proposed acquisition of 100% of the voting rights in Aurora Europe GmbH, Aurora Deutschland GmbH, and Aurora Produktions GmbH by Curaleaf Holdings.
On Nov. 2, 2026, Canada's Competition Bureau issued a no-action letter confirming that the Interim Commissioner of Competition had concluded her review and did not, at that time, intend to make an application under section 92 of the Competition Act (Canada) regarding the proposed acquisition of up to all of the issued and outstanding common shares of Aurora Cannabis Inc.
On Nov. 3, 2026, Germany's Federal Cartel Office confirmed that the proposed acquisition does not meet the conditions for prohibition under German competition law and may be implemented.
Curaleaf's enhanced premium bid of Oct. 6, 2026, to purchase all of the outstanding common shares of Aurora (the "offer") remains outstanding and is set to expire on Dec. 4, 2026, unless withdrawn or amended.
"With all required competition law clearances secured, the path is clear for Aurora shareholders to realize the value our offer provides," Curaleaf Board Chairman and CEO Boris Jordan said. "We appreciate the constructive engagement of the regulators who reviewed the transaction."
Curaleaf's required competition law reviews are complete, while Organigram's proposed acquisition remains subject to shareholder, court and regulatory approvals. Curaleaf believes these clearances strengthen its offer by providing greater certainty of completion and supporting a faster path to closing, subject to the offer's remaining conditions being satisfied or waived. The company believes Aurora shareholders should consider this advantage when evaluating the competing proposals.
